Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Adult
Aged
Aged, 80 and over
Dihydroxyphenylalanine
/ analogs & derivatives
Female
Humans
Intestinal Neoplasms
/ diagnostic imaging
Male
Middle Aged
Neuroendocrine Tumors
/ diagnostic imaging
Organometallic Compounds
Pancreatic Neoplasms
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
/ methods
Retrospective Studies
Stomach Neoplasms
/ diagnostic imaging
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
pubmed:
15
12
2020
medline:
4
3
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
The aim of this study was to compare retrospectively 18F-DOPA PET/CT versus 68Ga-DOTANOC PET/CT in a group of patients affected by midgut NET. Patients with histologically proven grade 1 or grade 2 midgut NET were explored after injection of 150 MBq of 68Ga-DOTANOC and 210 MBq of 18F-DOPA. The PET/CTs were analyzed visually and semiquantitatively at the patient level, regional level (7 defined regions), and lesion level (maximum of 5 lesions/organ). The criterion standard was determined on the basis of histology and imaging follow-up. Thirty patients (17 males and 13 females; median age, 63.5 years [37-82 years]) were included. Both PET/CTs were negative in 3 patients and positive in 25 patients. PET/CTs were discordant in 2 patients, with 18F-DOPA positive and 68Ga-DOTANOC negative. 18F-DOPA PET/CT detected more involved regions and more metastatic lesions than 68Ga-DOTANOC PET/CT in 6 (20%) and 10 (33.3%) patients, respectively. Of the 81 confirmed affected regions, 77 (95%) were detected by 18F-DOPA PET/CT and 71 (87.7%) by 68Ga-DOTANOC PET/CT (P < 0.0001). 18F-DOPA PET/CT detected significantly more lesions (211/221) than 68Ga-DOTANOC PET/CT (195/221), corresponding to a sensitivity of 95.5% and 88.2%, respectively (P < 0.0001). Tumor-to-background ratios were more favorable in liver for 18F-DOPA than for 68Ga-DOTANOC. Interestingly, a correlation was found between 18F-DOPA SUVmax and tumor burden and especially with the number of regions involved by the disease (P = 0.019). 18F-DOPA PET/CT is superior to 68Ga-DOTANOC PET/CT for the detection of lesions, and when available, this tracer may be recommended as the first-line examination for an accurate staging of midgut NET.
Identifiants
pubmed: 33315677
pii: 00003072-202103000-00001
doi: 10.1097/RLU.0000000000003450
doi:
Substances chimiques
68Ga-DOTANOC
0
Organometallic Compounds
0
fluorodopa F 18
2C598205QX
Dihydroxyphenylalanine
63-84-3
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-186Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: The authors declared no conflicts of interest. This study has been supported in part by the French National Agency for Research called “Investissements d’Avenir” IRON Labex n° ANR-11-LABX-0018-01 and INCa-DGOS-Inserm_12558 (SIRIC ILIAD).
Références
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol . 2017;3:1335–1342.
Klimstra DS, Kloppel G, La Rosa S, et al. In: WHO Classification of Tumours Editorial Board, editor Digestive System Tumours. WHO Classification of Tumours . 5th ed. Lyon, France: International Agency for Research on Cancer; 2019;309:16–19.
Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med . 2001;28:836–846.
Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging . 2010;37:2004–2010.
Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging . 2017;44:1588–1601.
Hoegerle S, Altehoefer C, Ghanem N, et al. Whole-body 18 F DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology . 2001;220:373–380.
Koopmans KP, de Vries EG, Kema IP, et al. Staging of carcinoid tumours with 18 F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol . 2006;7:728–734.
Montravers F, Grahek D, Kerrou K, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med . 2006;47:1455–1462.
Montravers F, Kerrou K, Nataf V, et al. Impact of fluorodihydroxyphenylalanine- 18 F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab . 2009;94:1295–1301.
Ambrosini V, Tomassetti P, Castellucci P, et al. Comparison between 68 Ga-DOTA-NOC and 18 F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging . 2008;35:1431–1438.
Haug A, Auernhammer CJ, Wängler B, et al. Intraindividual comparison of 68 Ga-DOTA-TATE and 18 F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging . 2009;36:765–770.
Putzer D, Gabriel M, Kendler D, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro- l -dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging . 2010;54:68–75.
Bergeret S, Charbit J, Ansquer C, et al. Novel PET tracers: added value for endocrine disorders. Endocrine . 2019;64:14–30.
Deroose CM, Hindié E, Kebebew E, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med . 2016;57:1949–1956.
Balogova S, Talbot JN, Nataf V, et al. 18 F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging . 2013;40:943–966.
Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med . 2012;14:71–81.
Berends AMA, Kerstens MN, Bolt JW, et al. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET ( 18 F-FDOPA-PET) performed for imaging of neuroendocrine tumors. Eur J Endocrinol . 2018;179:125–133.
Nadebaum DP, Lee ST, Nikfarjam M, et al. Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68 Ga-DOTATATE positron emission tomography: three case reports and a review of the literature. World J Nucl Med . 2018;17:195–197.
Yamaga LYI, Wagner J, Funari MBG. 68 Ga-DOTATATE PET/CT in nonneuroendocrine tumors: a pictorial essay. Clin Nucl Med . 2017;42:e313–e316.
Ilhan H, Fendler WP, Cyran CC, et al. Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann Surg Oncol . 2015;22:164–171.
Imperiale A, Rust E, Gabriel S, et al. 18 F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J Nucl Med . 2014;55:367–372.
Wild D, Bomanji JB, Benkert P, et al. Comparison of 68 Ga-DOTANOC and 68 Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med . 2013;54:364–372.
Nicolas GP, Schreiter N, Kaul F, et al. Sensitivity comparison of 68 Ga-OPS202 and 68 Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med . 2018;59:915–921.